Chennai Journal

Urea Cycle Disorder Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies – Acer Therapeutics, Poseide Therapeutics, Kaleido Biosciences

 Breaking News
  • No posts were found

Urea Cycle Disorder Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies – Acer Therapeutics, Poseide Therapeutics, Kaleido Biosciences

September 15
12:01 2023
Urea Cycle Disorder  Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - Acer Therapeutics, Poseide Therapeutics, Kaleido Biosciences
DelveInsight Business Research LLP
DelveInsight’s “Urea Cycle Disorders Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Urea Cycle Disorders, historical and forecasted epidemiology as well as the Urea Cycle Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Urea Cycle Disorders Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Urea Cycle Disorders, historical and forecasted epidemiology as well as the Urea Cycle Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Highlights for Anti- Hypertension Market 

  • Key companies working in Anti the hypertension market include Acer Therapeutics, Dimension Therapeutics, Callitas Therapeutics, Poseida Therapeutics, Promethera Biosciences, Arcturus Therapeutics, Kaleido Biosciences, Akaza Biopharma and many others. 

  • Key therapies in the Anti- hypertension market include HPN-100,  KB195, NaPBA, RAVICTI,  Sodium Benzoate, SYNB1020 and many others 

  • The Market Size for Anti- Hypertension market is expected to be USD XX Million by 2032.

  • The CAGR for Anti- Hypertension market is expected to be XX% 

Urea Cycle Disorder Overview 

Urea cycle disorders are the congenital error of nitrogen detoxification/arginine synthesis due to defects in the urea cycle enzymes such as carbamoylphosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase 1 (ARG1), leading to respective deficiencies (abbreviated CPS1D, OTCD, ASSD, ASLD and ARG1D). All the urea cycle disorders are inherited in an autosomal recessive pattern, except ornithine transcarbamoylase (OTC) deficiency, which is inherited as an X-linked trait; however, female carriers of the OTC gene can become symptomatic. According to  Van Leung-Pineda (2019), the prevalence of Urea Cycle Disorders s in the US is approximated to be 1 in 35,000, with two-thirds having symptoms in the neonatal period.

Click here to learn more about the Urea Cycle Disorder Market Landscape

The Report Covers the Urea Cycle Disorder  Epidemiology Segmented by:

  • Urea Cycle Disorder prevalent case 

  • Urea Cycle Disorder diagnosed cases 

  • Urea Cycle Disorder treatment case 

  • Urea Cycle Disorder incident cases 

Urea Cycle Disorder Market Outlook

The Urea Cycle Disorders market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Urea Cycle Disorders market trends by analyzing the impact of current Urea Cycle Disorders therapies on the market, Urea Cycle Disorders unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Urea Cycle Disorders market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Urea Cycle Disorders market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Urea Cycle Disorders market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Urea Cycle Disorder Market

  • Acer Therapeutics

  • Dimension Therapeutics

  • Callitas Therapeutics

  • Poseida Therapeutics

  • Promethera Biosciences

  • Arcturus Therapeutics

And many others 

Urea Cycle Disorder  Therapies Covered and Analyzed in the Report

  • ACER-001

  • AEB1102

  • DTX301

And many others 

Learn more about the Key Companies and Emerging Therapies in the Urea Cycle Disorder  Market

Table of Contents 

  1. Key Insights 

  2. Urea Cycle Disorder  Introduction 

  3. Executive Summary of Urea Cycle Disorder      –     

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Urea Cycle Disorder  Emerging Therapies

  7. Urea Cycle Disorder  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Urea Cycle Disorder Market Outlook

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services